Skip to main content
. 2021 Feb 15;13(2):149. doi: 10.3390/toxins13020149

Figure 3.

Figure 3

An overview of the mPFS and mOS in the context of melanoma [72] and renal cancer [81,83] mPFS, median progression-free survival, mOS, median overall survival.